AtriCure, Inc. (NASDAQ:ATRC) Receives $49.44 Consensus Price Target from Analysts

Shares of AtriCure, Inc. (NASDAQ:ATRC) have been given an average rating of “Buy” by the nine ratings firms that are covering the firm, MarketBeat reports. Nine investment analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $49.44.

ATRC has been the subject of a number of recent research reports. Canaccord Genuity Group cut their price objective on AtriCure from $66.00 to $52.00 and set a “buy” rating for the company in a research report on Friday, March 28th. Piper Sandler upped their target price on AtriCure from $40.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. JPMorgan Chase & Co. dropped their price target on AtriCure from $51.00 to $46.00 and set an “overweight” rating on the stock in a research note on Thursday, March 27th. Stifel Nicolaus boosted their price objective on AtriCure from $36.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Finally, Oppenheimer raised their target price on shares of AtriCure from $36.00 to $45.00 and gave the stock an “outperform” rating in a report on Thursday, February 13th.

Insider Buying and Selling at AtriCure

In other news, Director Karen Prange sold 6,100 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the sale, the director now directly owns 17,828 shares of the company’s stock, valued at $679,603.36. This trade represents a 25.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On AtriCure

Large investors have recently made changes to their positions in the company. Johnson Financial Group Inc. lifted its stake in AtriCure by 1,184.1% in the fourth quarter. Johnson Financial Group Inc. now owns 1,618 shares of the medical device company’s stock valued at $49,000 after acquiring an additional 1,492 shares during the last quarter. Heck Capital Advisors LLC bought a new position in shares of AtriCure during the 4th quarter valued at $60,000. Venturi Wealth Management LLC lifted its stake in shares of AtriCure by 1,337.6% in the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock valued at $69,000 after purchasing an additional 2,100 shares during the last quarter. KBC Group NV boosted its holdings in AtriCure by 65.3% in the fourth quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock worth $72,000 after purchasing an additional 932 shares in the last quarter. Finally, State of Wyoming increased its position in AtriCure by 21.9% during the fourth quarter. State of Wyoming now owns 2,481 shares of the medical device company’s stock worth $76,000 after buying an additional 446 shares during the last quarter. Institutional investors own 99.11% of the company’s stock.

AtriCure Stock Down 0.8 %

ATRC stock opened at $31.74 on Friday. The firm has a market cap of $1.55 billion, a PE ratio of -33.41 and a beta of 1.65. AtriCure has a 12 month low of $18.94 and a 12 month high of $43.11. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62. The firm has a 50 day simple moving average of $34.88 and a 200 day simple moving average of $34.49.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.